<div id="readability-page-1"><p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 23,187 shares of Hims &amp; Hers Health stock in a transaction on Monday, November 17th. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47. Following the transaction, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $2,585,239.92. This represents a 24.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link.</p><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>Oluyemi Okupe also recently made the following trade(s): </p><ul><li>On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $36.81, for a total value of $853,513.47. </li><li>On Friday, October 17th, Oluyemi Okupe sold 11,592 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $57.13, for a total value of $662,250.96. </li><li>On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $57.72, for a total value of $669,263.40. </li><li>On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $60.20, for a total value of $5,117,000.00. </li><li>On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $57.74, for a total value of $1,361,740.16. </li><li>On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. </li><li>On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $43.69, for a total transaction of $505,973.89. </li></ul><div><p><span></span><span>Get <strong>Hims &amp; Hers Health</strong> alerts:</span></p></div><h2>Hims &amp; Hers Health Stock Down 1.2%</h2><p>Shares of Hims &amp; Hers Health stock traded down $0.45 on Wednesday, hitting $35.81. The company had a trading volume of 20,738,539 shares, compared to its average volume of 32,329,717. The stock has a 50-day moving average of $50.12 and a 200-day moving average of $51.42. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. Hims &amp; Hers Health, Inc. has a twelve month low of $21.36 and a twelve month high of $72.98. The firm has a market capitalization of $8.15 billion, a P/E ratio of 66.31, a P/E/G ratio of 7.08 and a beta of 2.20. </p><ul><li>Why Hims &amp; Hers Stock May Be a Buy After Mixed Q3 Results</li></ul><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims &amp; Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company's revenue was up 49.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share.  Hims &amp; Hers Health has set its FY 2025 guidance at  EPS. Q4 2025 guidance at  EPS. Research analysts predict that  Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year. </p><p>Hims &amp; Hers Health announced that its Board of Directors has approved a share repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in  outstanding  shares. This repurchase authorization permits the company to repurchase up to 3% of its stock  through open market purchases. Stock  repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued. </p><h2>Institutional Inflows and Outflows</h2><ul><li>Hims &amp; Hers Short Interest Nears All-Time High, Buy The Dip?</li></ul><p>A number of large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC raised its position in  Hims &amp; Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period.  Invesco Ltd. grew its stake in shares of  Hims &amp; Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock valued at $127,237,000 after buying an additional 2,128,587 shares in the last quarter.  Nuveen LLC acquired a new stake in shares of  Hims &amp; Hers Health in the first quarter valued at $58,403,000.  Clear Street LLC purchased a new stake in shares of  Hims &amp; Hers Health in the 2nd quarter valued at $83,582,000.  Finally, Norges Bank acquired a new position in  Hims &amp; Hers Health during the 2nd quarter worth about $78,464,000. Institutional investors and hedge funds own  63.52% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of research firms recently issued reports on HIMS. UBS Group  set a $32.00 price objective on Hims &amp; Hers Health in a report on Tuesday, November 4th. Needham &amp; Company LLC  reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a research note on Tuesday, August 5th. BTIG Research  reissued a &#34;buy&#34; rating and issued a $85.00 price objective on shares of Hims &amp; Hers Health in a research report on Tuesday, November 4th. Bank of America raised their target price on shares of Hims &amp; Hers Health from $28.00 to $32.00 and gave the company an &#34;underperform&#34; rating in a research report on Tuesday, November 4th. Finally, Zacks Research cut shares of Hims &amp; Hers Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 19th. Two investment analysts have rated the stock with a Buy rating, ten have issued  a Hold rating and three have assigned  a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of &#34;Reduce&#34; and a consensus price target of $45.27.</p><p><b>Read Our Latest Report on Hims &amp; Hers Health</b></p><h2>About Hims &amp; Hers Health</h2> (Get Free Report)<p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. </p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Hims &amp; Hers Health</li><li>Why Invest in High-Yield Dividend Stocks?</li><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li><li>How is Compound Interest Calculated?</li><li>End the Year Strong With These 3 Comeback Champions</li><li>How to Calculate Options Profits</li><li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p><p>While Hims &amp; Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HIMS

<p>Hims & Hers Health CFO Oluyemi Okupe sold 23,187 shares at $36.81 each, totaling $853,513.47, reducing his stake by 24.82%. The company announced a $250 million share repurchase plan, indicating undervaluation. Recent earnings missed estimates, but revenue rose 49.2% year-over-year. The stock's price has fluctuated, with a 12-month low of $21.36 and high of $72.98. Institutional investors are actively trading the stock.</p>

Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 23,187 Shares